Highest-materiality recent filing
Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M
Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.
Lucid Diagnostics closes $18M underwritten offering of 18M shares at $1.00/share
Closed sale of 18,000,000 shares at $1.00/share; gross proceeds $18M, net proceeds ~$16.8M.
Lucid Diagnostics prices $18M underwritten offering of 18M shares at $1.00 per share
Offering of 18,000,000 common shares at $1.00 each; gross proceeds ~$18M.
Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded
Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).
Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.
Lucid Diagnostics appoints John R. Palumbo, healthcare veteran, to board effective Sept 22, 2025
John R. Palumbo appointed as Class B director, effective September 22, 2025, designated by convertible note holders.
Lucid Diagnostics closes $28.75M public offering of 28.75M shares at $1.00/share
Closed underwritten public offering of 28,750,000 shares at $1.00 per share, including full exercise of underwriters' option for 3,750,000 additional shares.
Lucid Diagnostics prices $25M public offering of 25M shares at $1.00 per share
Priced 25,000,000 shares of common stock at $1.00 per share; gross proceeds ~$25M before expenses.
Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering
Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.
Lucid Diagnostics shareholders re-elect Lapidus and Sokolov, approve stock issuance, ratify auditor
70.9% of shares represented at June 18 annual meeting; all management proposals passed.
Lucid Diagnostics enters $25M ATM equity offering with Maxim Group
Up to $25M of common stock may be sold at-the-market via Maxim Group as agent.
Lucid Diagnostics Q1 2025 revenue $0.8M, net loss $36M; raises ~$46.7M in equity
Revenue of $0.8M from 3,034 EsoGuard tests; GAAP net loss $36.0M ($0.52/share); adjusted loss $11.2M ($0.16/share).
Lucid Diagnostics changes auditor to CBIZ CPAs after Marcum acquisition
Marcum resigned as auditor on April 23, 2025; CBIZ CPAs engaged same day with audit committee approval.
Lucid Diagnostics closes $16.1M public offering of 14.4M shares at $1.20/share
Closed sale of 14,375,000 shares of common stock at $1.20/share; underwriters' option exercised in full.
Lucid Diagnostics prices $15M public offering of 12.5M shares at $1.20 per share
Gross proceeds ~$15M from 12.5M shares at $1.20; underwriters have 45-day option for 1.875M additional shares.
Lucid Diagnostics reports Q4 EsoGuard revenue $1.2M, record 4,042 tests processed
Record 4,042 EsoGuard tests processed in Q4 2024, up 45% sequentially and 84% year-over-year.
Lucid Diagnostics closes $15.3M registered direct offering of 13.9M shares at $1.10/share
Closed offering of 13,939,331 common shares at $1.10 per share for gross proceeds of $15.3M.
Lucid Diagnostics terminates ATM equity offering program after minimal sales
Terminated ATM prospectus supplement effective March 4, 2025; no new sales without new filing.
Lucid Diagnostics raises $15.3M in registered direct offering of 13.9M shares at $1.10/share
Gross proceeds of ~$15.3M from sale of 13,939,331 shares at $1.10/share; net proceeds ~$14.5M after fees/expenses.
Lucid Diagnostics regains Nasdaq minimum bid price compliance
Received Nasdaq notification on Feb 24, 2025 confirming compliance with $1 minimum bid price rule.
Lucid Diagnostics receives Nasdaq extension until June 16, 2025 to regain bid price compliance
Received Nasdaq letter granting additional 180 days (to June 16, 2025) to meet $1 minimum bid price.
Sold $21.95M principal amount Senior Secured Convertible Notes, net proceeds $18.3M after repaying 2023 note.
Lucid Diagnostics sells $21.75M in convertible notes to redeem existing 2023 note
Aggregate $21.75M in Senior Secured Convertible Notes sold to accredited investors.
EsoGuard revenue $1.2M, up 20% sequentially from Q2 2024 and 50% YoY from Q3 2023.
Lucid Diagnostics redeems 2023 convertible note, issues $1.00/sh 12% secured notes due 2029
Notice to redeem 2023 Senior Convertible Note at optional redemption price; payment due within 10-20 business days.
Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M
EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.
Lucid Diagnostics shareholders approve increase in authorized shares, re-elect directors
Stockholders re-elected Dr. Lishan Aklog, Debra White, and Dennis Matheis as Class C directors.
Lucid Diagnostics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notice on June 21, 2024: closing bid price below $1 for 30 consecutive business days.
Lucid Diagnostics reschedules annual meeting to July 23, new record date May 29
Annual meeting moved from June 20 to July 23, 2024 at 11:00 a.m. ET.
Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially
EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.
Lucid Diagnostics closes $11.6M Series B-1 preferred offering; appoints Dennis Matheis to board
Gross proceeds from combined Series B / B-1 offering total $29.8M; $11.6M from Series B-1, $18.6M from prior Series B.
Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers
EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.
Lucid Diagnostics completes $18.16M Series B Preferred offering and exchange of Series A/A-1 shares
Gross proceeds of $18.16M: $12.495M from new subscriptions and $5.67M from Series A-1 sales immediately exchanged.
Effective May 6, 2024, the board of directors of the Company appointed Dennis Matheis as a Class A director of the Company.
Max materiality 0.80 · Median 0.65 · Most common event other_material